Compare BLBD & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | NNNN |
|---|---|---|
| Founded | 1927 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | BLBD | NNNN |
|---|---|---|
| Price | $49.27 | $21.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $64.60 | N/A |
| AVG Volume (30 Days) | ★ 472.6K | 35.9K |
| Earning Date | 02-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.79 | N/A |
| EPS | ★ 3.88 | 0.06 |
| Revenue | ★ $1,480,099,000.00 | $6,920,153.00 |
| Revenue This Year | $4.86 | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | ★ $12.82 | $328.91 |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $30.04 | $5.18 |
| 52 Week High | $61.95 | $55.65 |
| Indicator | BLBD | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 38.85 |
| Support Level | $48.75 | $18.50 |
| Resistance Level | $50.81 | $31.52 |
| Average True Range (ATR) | 1.50 | 4.57 |
| MACD | 0.22 | -1.76 |
| Stochastic Oscillator | 59.02 | 14.29 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.